

# Ernest H Choy

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9316799/ernest-h-choy-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

183  
papers

8,431  
citations

48  
h-index

87  
g-index

215  
ext. papers

10,466  
ext. citations

4.8  
avg, IF

6.53  
L-index

#	Paper	IF	Citations
183	OA05 Lower incidence of COVID-19 but higher mortality in patients with inflammatory arthritis compared to controls in Wales, United Kingdom: a population epidemiological study. <i>Rheumatology</i> , 2022, 61,	3.9	1
182	Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritis. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkaa063	1.1	
181	Considering Immuno-autonomics in Stratifying Successful Treatment of Rheumatoid Arthritis with Tumor Necrosis Factor Inhibition: Comment on Cohen et al. <i>Rheumatol Ther</i> 2021 June 19. <i>Rheumatology and Therapy</i> , 2021, 1	4.4	
180	The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis. <i>Rheumatology</i> , 2021, 60, 2852-2861	3.9	2
179	Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. <i>European Urology Focus</i> , 2021, 7, 1084-1091	5.1	0
178	Rheumatologists at a crossroads: blocking tumour necrosis factor or interleukin 6 in disease-modifying anti-rheumatic drug inadequate responder patients with rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 4953-4955	3.9	
177	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102849	13.6	3
176	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48	2.4	61
175	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 31-35	2.4	61
174	Differential Binding of Sarilumab and Tocilizumab to IL-6R $\alpha$ and Effects of Receptor Occupancy on Clinical Parameters. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 714-724	2.9	10
173	Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab042	1.1	0
172	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 305-317	4.0	42
171	C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 219-229	5.3	19
170	The Jak/STAT pathway: A focus on pain in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 278-284	5.3	22
169	Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study. <i>BMC Rheumatology</i> , 2021, 5, 3	2.9	
168	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021,	2.4	6
167	Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1800-1809	8.5	2

166	Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 1661-1675	4.4	3
165	Fibromyalgia position paper. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 130, 186-193	2.2	1
164	Diagnostic and therapeutic care pathway for fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 130, 120-127	2.2	
163	Diagnostic and therapeutic care pathway for fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 120-127	2.2	0
162	Fibromyalgia position paper. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 186-193	2.2	5
161	CD28 Cells Are Increased in Early Rheumatoid Arthritis and Are Linked With Cytomegalovirus Status. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 129	4.9	1
160	Cumulative patient-based disease activity monitoring in rheumatoid arthritis - predicts sustained remission, flare and treatment escalation. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 749-758	5.3	0
159	Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 316-323	2.4	23
158	Individual therapeutic DAS28-d responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies. <i>Rheumatology International</i> , <b>2020</b> , 40, 747-755	3.6	
157	Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1456-1466	9.5	17
156	Translating IL-6 biology into effective treatments. <i>Nature Reviews Rheumatology</i> , <b>2020</b> , 16, 335-345	8.1	164
155	Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the TAIL study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e21628-e21628	2.2	
154	B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 714-725	9.5	18
153	Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. <i>European Journal of Cancer</i> , <b>2020</b> , 138, 202-211	7.5	10
152	O07 Randomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy. <i>Rheumatology</i> , <b>2020</b> , 59,	3.9	1
151	Transforming clinical trials in rheumatology: towards patient-centric precision medicine. <i>Nature Reviews Rheumatology</i> , <b>2020</b> , 16, 590-599	8.1	15
150	Practice Advisory on the Appropriate Use of NSAIDs in Primary Care. <i>Journal of Pain Research</i> , <b>2020</b> , 13, 1925-1939	2.9	2
149	Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 669-671	2.4	5

148	Using Visual Timelines in Telephone Interviews: Reflections and Lessons Learned From the Star Family Study. <i>International Journal of Qualitative Methods, The</i> , <b>2020</b> , 19, 1609406920913675	3.3	2
147	Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. <i>Cell Reports</i> , <b>2019</b> , 28, 2455-2470.e5	10.6	100
146	The need for comparative data in spondyloarthritis. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 32	5.7	3
145	AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). <i>BMC Rheumatology</i> , <b>2019</b> , 3, 19	2.9	8
144	069 High baseline serum IL-6 identifies a subgroup of rheumatoid arthritis patients with rapid joint damage and clinical progression and predicts increased sarilumab treatment response. <i>Rheumatology</i> , <b>2019</b> , 58,	3.9	5
143	Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study. <i>Rheumatology Advances in Practice</i> , <b>2019</b> , 3, rkz010	1.1	4
142	Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naïve patients with psoriatic arthritis. <i>Journal of Comparative Effectiveness Research</i> , <b>2019</b> , 8, 497-510	2.1	11
141	Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. <i>European Urology</i> , <b>2019</b> , 76, 73-81	10.2	74
140	Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs. <i>Advances in Therapy</i> , <b>2019</b> , 36, 817-827	4.1	4
139	Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 761-772	2.4	96
138	Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1355-1359	4.1	1
137	Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1406-1408	4.1	4
136	"Nobody knows, or seems to know how rheumatology and breastfeeding works": Women@ experiences of breastfeeding whilst managing a long-term limiting condition - A qualitative visual methods study. <i>Midwifery</i> , <b>2019</b> , 78, 91-96	2.8	8
135	Neuropathic-like pain in psoriatic arthritis: evidence of abnormal pain processing. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 3153-3159	3.9	8
134	Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis. <i>Rheumatology</i> , <b>2019</b> , 58, v51-v55	3.9	9
133	Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations. <i>Health Technology Assessment</i> , <b>2019</b> , 23, 1-130	4.4	7
132	Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison. <i>European Journal of Rheumatology</i> , <b>2019</b> , 6, 113-121	1.7	4
131	Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT). <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 465-472	2.4	28

130	Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor inhibitors: systematic literature review and network meta-analyses. <i>RMD Open</i> , <b>2019</b> , 5, e000798	5.9	12
129	FRI0106 SARILUMAB AND TOCILIZUMAB RECEPTOR OCCUPANCY (RO), AND EFFECTS ON C-REACTIVE PROTEIN (CRP) LEVELS, IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) <b>2019</b> ,		1
128	Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case-control comparison. <i>BMJ Open</i> , <b>2019</b> , 9, e031365	3	59
127	Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1642-1652	2.4	43
126	Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 685-695	9.5	21
125	Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. <i>Rheumatology</i> , <b>2019</b> , 58, 1056-1064	3.9	6
124	Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 958-966	5.3	2
123	Clinical significance of Janus Kinase inhibitor selectivity. <i>Rheumatology</i> , <b>2019</b> , 58, 953-962	3.9	89
122	The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 694-704	2.2	20
121	An evidence-based review of pregabalin for the treatment of fibromyalgia. <i>Current Medical Research and Opinion</i> , <b>2018</b> , 34, 1397-1409	2.5	13
120	Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. <i>Rheumatology</i> , <b>2018</b> , 57, 1885-1895	3.9	51
119	Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. <i>Rheumatology</i> , <b>2018</b> , 57, 499-507	3.9	24
118	The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review. <i>Drug Safety</i> , <b>2018</b> , 41, 473-488	5.1	24
117	Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 48, 367-373	5.3	18
116	Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. <i>Rheumatology</i> , <b>2018</b> , 57, 1982-1990	3.9	15
115	Optimized Peptide-MHC Multimer Protocols for Detection and Isolation of Autoimmune T-Cells. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1378	8.4	33
114	Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria?. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 33-35	13.6	24
113	Identifying the unmet information and support needs of women with autoimmune rheumatic diseases during pregnancy planning, pregnancy and early parenting: mixed-methods study. <i>BMC Rheumatology</i> , <b>2018</b> , 2, 21	2.9	19

112	Interleukin 6: The biology behind the therapy <b>2018</b> , 2, 2-6		6
111	Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials. <i>Rheumatology Advances in Practice</i> , <b>2018</b> , 2, rky045	1.1	1
110	179 Neuropathic-like pain is common in psoriatic arthritis. <i>Rheumatology</i> , <b>2018</b> , 57,	3.9	1
109	Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe. <i>RMD Open</i> , <b>2018</b> , 4, e000799	5.9	19
108	Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , <b>2018</b> , 7, 1107-1123	2.1	24
107	Functional MRI in rheumatic diseases with a focus on fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 114, 82-85	2.2	3
106	Participants' experiences of an Education, self-management and upper extremity eExercise Training for people with Rheumatoid Arthritis programme (EXTRA). <i>Physiotherapy</i> , <b>2017</b> , 103, 430-438	3	7
105	Alterations to adipose tissue morphology during inflammatory arthritis is indicative of vasculopathology in DBA/1 mice. <i>Adipocyte</i> , <b>2017</b> , 6, 87-101	3.2	3
104	Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1078-1085	2.4	53
103	Lower Placebo Responses After Long-Term Exposure to Fibromyalgia Pain. <i>Journal of Pain</i> , <b>2017</b> , 18, 835-843	5.2	22
102	EULAR recommendations for management of fibromyalgia. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, e54	2.4	23
101	Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1484-1494	4.7	30
100	Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1679-1687	2.4	99
99	Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients. <i>Rheumatology and Therapy</i> , <b>2017</b> , 4, 57-69	4.4	10
98	Interleukin-6 as a Multifunctional Regulator: Inflammation, Immune Response, and Fibrosis. <i>Journal of Scleroderma and Related Disorders</i> , <b>2017</b> , 2, S1-S5	2.3	52
97	The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1969-1977	9.5	74
96	Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1536-1543	4.1	16
95	Synovial tissue research: a state-of-the-art review. <i>Nature Reviews Rheumatology</i> , <b>2017</b> , 13, 463-475	8.1	107

94	Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. <i>Seminars in Arthritis and Rheumatism</i> , <b>2017</b> , 46, 699-708	5.3	16
93	Defining criteria for rheumatoid arthritis patient-derived disease activity score that correspond to Disease Activity Score 28 and Clinical Disease Activity Index based disease states and response criteria. <i>Rheumatology</i> , <b>2016</b> , 55, 1954-1958	3.9	6
92	The biology behind interleukin-6 targeted interventions. <i>Current Opinion in Rheumatology</i> , <b>2016</b> , 28, 152-159	5.0	36
91	Current treatments to counter sleep dysfunction as a pathogenic stimulus of fibromyalgia. <i>Pain Management</i> , <b>2016</b> , 6, 339-46	2.3	5
90	Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter--Determining Validation Requirements. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 208-13	4.1	22
89	Defining Disease Phenotypes in Primary Care Electronic Health Records by a Machine Learning Approach: A Case Study in Identifying Rheumatoid Arthritis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0154515	3.7	42
88	Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. <i>Pain</i> , <b>2016</b> , 157, 1836-1850	8	106
87	Biologic interventions for fatigue in rheumatoid arthritis. <i>The Cochrane Library</i> , <b>2016</b> , CD008334	5.2	37
86	Ms. A.M. Taylor, et al reply. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 826	4.1	
85	Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. <i>RMD Open</i> , <b>2016</b> , 2, e000225	5.9	42
84	Fibromyalgia and Chronic Pain Syndromes: A White Paper Detailing Current Challenges in the Field. <i>Clinical Journal of Pain</i> , <b>2016</b> , 32, 737-46	3.5	58
83	Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. <i>Lancet, The</i> , <b>2016</b> , 388, 239-47	4.0	76
82	Anti cytokine therapy in chronic inflammatory arthritis. <i>Cytokine</i> , <b>2016</b> , 86, 92-99	4	32
81	Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musculoskeletal Group and OMERACT. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1943-1946	4.1	7
80	Pharmacologic modulation of hand pain in osteoarthritis: a double-blind placebo-controlled functional magnetic resonance imaging study using naproxen. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 741-751	9.5	22
79	The role of sleep in pain and fibromyalgia. <i>Nature Reviews Rheumatology</i> , <b>2015</b> , 11, 513-20	8.1	121
78	Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis. <i>Journal of Immunology</i> , <b>2015</b> , 194, 3029-34	5.3	26
77	Is Chronic Pain a Disease in Its Own Right? Discussions from a Pre-OMERACT 2014 Workshop on Chronic Pain. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1947-1953	4.1	15

76	Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2185-9	4.1	34
75	Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party. <i>Rheumatology and Therapy</i> , <b>2015</b> , 2, 113-125	4.4	9
74	Response to Comment on "Functional Analysis of a Complement Polymorphism (rs17611) Associated with Rheumatoid Arthritis". <i>Journal of Immunology</i> , <b>2015</b> , 195, 4	5.3	2
73	Death Receptor 3 (TNFRSF25) Increases Mineral Apposition by Osteoblasts and Region Specific New Bone Formation in the Axial Skeleton of Male DBA/1 Mice. <i>Journal of Immunology Research</i> , <b>2015</b> , 2015, 901679	4.5	7
72	Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. <i>Rheumatology</i> , <b>2015</b> , 54, 1050-5	3.9	17
71	Evaluation of the Disease Activity Score in Twenty-Eight Joints-Based Flare Definitions in Rheumatoid Arthritis: Data From a Three-Year Clinical Trial. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 1762-6	4.7	9
70	Economic evaluation of a brief education, self-management and upper limb exercise training in people with rheumatoid arthritis (EXTRA) programme: a trial-based analysis. <i>Rheumatology</i> , <b>2015</b> , 54, 302-9	3.9	12
69	Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1781-7	2.4	20
68	Education, self-management, and upper extremity exercise training in people with rheumatoid arthritis: a randomized controlled trial. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 217-27	4.7	60
67	Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: data from the randomized, double-blind, COMBO-DN study. <i>Pain</i> , <b>2014</b> , 155, 2171-9	8	87
66	The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. <i>Rheumatology</i> , <b>2014</b> , 53, 1344-6	3.9	14
65	Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 799-809	4.1	56
64	The future of biological agents in the treatment of rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , <b>2014</b> , 9, 475-486	1.5	
63	Segregating the cerebral mechanisms of antidepressants and placebo in fibromyalgia. <i>Journal of Pain</i> , <b>2014</b> , 15, 1328-37	5.2	12
62	Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1000-4	4.1	28
61	Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. <i>Rheumatology</i> , <b>2014</b> , 53, 2143-54	3.9	189
60	Updating the OMERACT filter: implications for patient-reported outcomes. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1011-5	4.1	48
59	Updating the OMERACT filter: core areas as a basis for defining core outcome sets. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 994-9	4.1	19



58	Clinical experience of IL-6 blockade in rheumatic diseases - implications on IL-6 biology and disease pathogenesis. <i>Seminars in Immunology</i> , <b>2014</b> , 26, 97-104	10.7	23
57	Outcome measures in rheumatoid arthritis. <i>Indian Journal of Rheumatology</i> , <b>2013</b> , 8, S31-S35	0.5	1
56	Overlapping structural and functional brain changes in patients with long-term exposure to fibromyalgia pain. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 3293-303		130
55	The problem of choice: current biologic agents and future prospects in RA. <i>Nature Reviews Rheumatology</i> , <b>2013</b> , 9, 154-63	8.1	101
54	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 482-92	2.4	87
53	Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1800-5	2.4	85
52	Enhanced and persistent levels of interleukin (IL)-17+ CD4+ T cells and serum IL-17 in patients with early inflammatory arthritis. <i>Clinical and Experimental Immunology</i> , <b>2013</b> , 174, 292-301	6.2	42
51	Non-pharmacological interventions for fatigue in rheumatoid arthritis. <i>The Cochrane Library</i> , <b>2013</b> , CD009322		97
50	Cognitive behavioural therapies for fibromyalgia. <i>The Cochrane Library</i> , <b>2013</b> , CD009796	5.2	83
49	Alterations in resting-state regional cerebral blood flow demonstrate ongoing pain in osteoarthritis: An arterial spin-labeled magnetic resonance imaging study. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 3936-46		50
48	Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. <i>Rheumatology</i> , <b>2012</b> , 51 Suppl 5, v3-11	3.9	515
47	The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective. <i>Journal of Medical Economics</i> , <b>2012</b> , 15, 481-92	2.4	13
46	Pain thresholds in rheumatoid arthritis: the effect of tender point counts and disease duration. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 28-31	4.1	37
45	Evaluation of patient-rated stiffness associated with fibromyalgia: a post-hoc analysis of 4 pooled, randomized clinical trials of duloxetine. <i>Clinical Therapeutics</i> , <b>2012</b> , 34, 824-37	3.5	14
44	Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 935-42	2.4	40
43	Variation in the use of biologics in the management of rheumatoid arthritis across the UK. <i>Current Medical Research and Opinion</i> , <b>2012</b> , 28, 1733-41	2.5	8
42	Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. <i>Rheumatology</i> , <b>2012</b> , 51, 1226-34	3.9	56
41	Remission in early rheumatoid arthritis: predicting treatment response. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 470-5	4.1	29

40	Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1855-60	2.4	112
39	Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. <i>Rheumatology</i> , <b>2011</b> , 50, 518-31	3.9	156
38	A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. <i>Seminars in Arthritis and Rheumatism</i> , <b>2011</b> , 41, 335-45.e6	5.3	47
37	Serological investigation of IgG levels and subclasses in rheumatoid arthritis patients following ingestion of bovine type II collagen: results of a double blind, randomised controlled trial. <i>Clinical Rheumatology</i> , <b>2011</b> , 30, 193-9	3.9	2
36	New biologics for rheumatoid arthritis. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , <b>2011</b> , 41, 234-7	0.9	2
35	Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. <i>Rheumatology</i> , <b>2010</b> , 49, 15-24	3.9	169
34	Fibromyalgic rheumatoid arthritis and disease assessment. <i>Rheumatology</i> , <b>2010</b> , 49, 924-8	3.9	90
33	Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. <i>Current Medical Research and Opinion</i> , <b>2010</b> , 26, 965-75	2.5	18
32	Clinical Domains of Fibromyalgia Syndrome: Determination through the OMERACT Process. <i>Journal of Musculoskeletal Pain</i> , <b>2010</b> , 18, 380-386		3
31	The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. <i>Rheumatology</i> , <b>2010</b> , 49, 295-307	3.9	265
30	The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2010</b> , 2, 247-56	3.8	180
29	A patient survey of the impact of fibromyalgia and the journey to diagnosis. <i>BMC Health Services Research</i> , <b>2010</b> , 10, 102	2.9	142
28	Anxiety and depressive symptoms in fibromyalgia are related to poor perception of health but not to pain sensitivity or cerebral processing of pain. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 3488-95		67
27	RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonists. <i>Nature Clinical Practice Rheumatology</i> , <b>2009</b> , 5, 66-7		7
26	What makes patients with fibromyalgia feel better? Correlations between Patient Global Impression of Improvement and changes in clinical symptoms and function: a pooled analysis of 4 randomized placebo-controlled trials of duloxetine. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 2517-22	4.1	25
25	Fibromyalgia syndrome module at OMERACT 9: domain construct. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 2318-29	4.1	163
24	Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 2330-4	4.1	56
23	Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials. <i>Clinical Rheumatology</i> , <b>2009</b> , 28, 1035-44	3.9	35

22	Key symptom domains to be assessed in fibromyalgia (outcome measures in rheumatoid arthritis clinical trials). <i>Rheumatic Disease Clinics of North America</i> , <b>2009</b> , 35, 329-37	2.4	25
21	Systematic review of discriminating power of outcome measures used in clinical trials of fibromyalgia. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 2094-105	4.1	34
20	Clinical and radiological features of rheumatoid arthritis in British black Africans. <i>Clinical Rheumatology</i> , <b>2008</b> , 27, 97-100	3.9	6
19	Inhibiting interleukin-6 in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , <b>2008</b> , 10, 413-7	4.9	6
18	Development and validation of a patient-based disease activity score in rheumatoid arthritis that can be used in clinical trials and routine practice. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 59, 192-9		29
17	Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 2642-51		135
16	Drug use and toxicity in psoriatic disease: focus on methotrexate. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 1454-7	4.1	28
15	T cells in psoriatic arthritis. <i>Current Rheumatology Reports</i> , <b>2007</b> , 9, 437-41	4.9	17
14	Does the Health Assessment Questionnaire predict 5-year quality of life in early RA?. <i>Nature Clinical Practice Rheumatology</i> , <b>2007</b> , 3, 380-1		1
13	Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 3069-78	2.5	7
12	Fibromyalgia syndrome. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 1415-25	4.1	121
11	The Longitudinal Examination of Arthritis Pain (LEAP) study: relationships between weekly fluctuations in patient-rated joint pain and other health outcomes. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 2291-300	4.1	56
10	Comparing methods for the diagnosis of fibromyalgia. <i>Nature Clinical Practice Rheumatology</i> , <b>2006</b> , 2, 244-5		
9	Rheumatoid arthritis: non-tumor necrosis factor targets. <i>Current Opinion in Rheumatology</i> , <b>2005</b> , 17, 242-53		14
8	Non-tumor necrosis factor biological therapies for rheumatoid arthritis. <i>APLAR Journal of Rheumatology</i> , <b>2005</b> , 8, 77-83		2
7	Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 3279-89		712
6	Clinical experience with inhibition of interleukin-6. <i>Rheumatic Disease Clinics of North America</i> , <b>2004</b> , 30, 405-15, viii	2.4	25
5	Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis. <i>Cytokine</i> , <b>2004</b> , 28, 158-61	4	3

4	Use of two-dimensional gel electrophoresis to measure changes in synovial fluid proteins from patients with rheumatoid arthritis treated with antibody to CD4. <i>Vaccine Journal</i> , <b>2001</b> , 8, 105-11		33
3	Anti-CD4 monoclonal antibodies in rheumatoid arthritis. <i>Seminars in Immunopathology</i> , <b>1998</b> , 20, 261-73		10
2	Drug treatment of rheumatic diseases in the 1990s. Achievements and future developments. <i>Drugs</i> , <b>1997</b> , 53, 337-48	12.1	8
1	Chimaeric anti-CD4 monoclonal antibody cross-linked by monocyte Fc gamma receptor mediates apoptosis of human CD4 lymphocytes. <i>European Journal of Immunology</i> , <b>1993</b> , 23, 2676-81	6.1	32